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IgG3 is the IgG subclass with the strongest effector functions among all four IgG sub-
classes and the highest degree of allelic variability among all constant immunoglobulin 
genes. Due to its genetic position, IgG3 is often the first isotype an antibody switches to 
before IgG1 or IgG4. Compared with the other IgG subclasses, it has a reduced half-life 
which is probably connected to a decreased affinity to the neonatal Fc receptor (FcRn). 
However, a few allelic variants harbor an amino acid replacement of His435 to Arg that 
reverts the half-life of the resulting IgG3 to the same level as the other IgG subclasses. 
Because of its functional impact, we hypothesized that the p.Arg435His variation could 
be associated with susceptibility to autoantibody-mediated diseases like pemphigus 
vulgaris (PV) and bullous pemphigoid (BP). Using a set of samples from German, Turkish, 
Egyptian, and Iranian patients and controls, we were able to demonstrate a genetic 
association of the p.Arg435His variation with PV risk, but not with BP risk. Our results 
suggest a hitherto unknown role for the function of IgG3 in the pathogenesis of PV.
Keywords: immunology, dermatology, autoantibodies, allotype, pemphigus, pemphigoid, half-life, functional 
genetics
Figure 1 | Alignment of human IgG gene alleles. Alignment of all human IgG alleles listed in IMGT [http://www.imgt.org (Accessed: 15 March, 2015)], including 
GenBank accession number, gene names, isotype, allele numbering, and allotype numbering. Primer annealing sites for KASP and IgG3-specific PCR are shaded in 
blue, green, and red, respectively. Nucleotides unique in IgG3 (IgG3 specific) and the g.1053927G>A variation (p.Arg435His) are indicated with a red border. The full 
DNA sequence is shown for the reference sequence (AJ390235), for all other sequences, all bases except those that differ from the reference are masked by a dot. 
The amino acid sequence of the reference sequence is shown on the bottom site, together with the PCR fragment amplified for Sanger sequencing. The IGHG3 
alleles that contain the g.1053927G>A variation are highlighted in pink (G3m15). A marker for DNA positions within the alignment set is given on the top scale.
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inTrODucTiOn
Of the four human IgG subclasses, IgG3 (gene IGHG3) exhibits 
the strongest capabilities to activate complement and effector 
cells of the innate immune system (1). Compared with the other 
IgG subclasses, IgG3 has a reduced half-life which is probably 
caused by a decreased affinity to FcRn (2). FcRn is involved in 
IgG transport across mucosal cells and the placenta. Moreover, 
FcRn is responsible for the exceptionally long half-life of IgG, 
and it rescues IgG from lysosomal degradation by recycling it 
back to the surface in endothelial cells. It further appears to be 
involved in IgG-mediated phagocytosis (3). The reduced half-life 
of IgG3 appears to be caused by an amino acid replacement at 
residue 435, where this IgG subclass typically carries an arginine 
instead of a histidine like the other IgG subclasses. From the 19 
different alleles that the IMGT (ImMunoGeneTics information) 
database1 lists for IGHG3, 3 alleles contain a histidine instead 
of an arginine at this position (IgG3:p.Arg435His variation, 
NG_001019.5:g.1053927G>A, RefSNP rs4042056, Figure  1). 
These three alleles are associated with the G3m15 and G3m16 
allotypes which are quite rare in the European population and 
more frequent in Asia and Africa (4). The histidine residue at 
position 435 leads to a higher affinity of IgG3 to FcRn and, con-
sequently, to a prolonged half-life and most likely to an increased 
bioavailability in extravascular tissues (2).
Immunoglobulin allotypes represent serological features 
of genetic variations within the constant domains. Gm–Am 
1 http://www.imgt.org (Accessed: 25 January, 2017).
allotypes are inherited as fixed combination, also termed Gm–
Am haplotypes (5). They have been associated with various 
autoimmune diseases and different immune responses to bacte-
rial infections (6). Of note, an association with immunoglobulin 
kappa light chain allotypes (Km allotypes) has been described 
for bullous pemphigoid (BP) but not for pemphigus vulgaris 
(PV) (7). However, the underlying mechanisms remain unex-
plained. Genetic polymorphisms with functional impact like 
the p.Arg435His variation of IgG3 might affect the etiology and 
pathogenesis of associated diseases, including autoantibody-
mediated diseases. Therefore, this study was conducted to 
elucidate a possible association of the p.Arg435His variation 
with PV. PV is a severe autoimmune blistering disorder of the 
skin and surface-close mucous membranes, characterized by 
autoantibodies against desmosomal proteins of the epidermis 
and epithelia of mucosal membranes: desmoglein 3 and, in the 
mucocutaneous variant of PV, also desmoglein 1. IgG1 and IgG4, 
the most frequent IgG subclasses, have been demonstrated to 
cause acantholysis (8, 9). IgG3, however, is often the first IgG 
subclass that appears immediately after the B  cell switch from 
IgM (10). IgG anti-Dsg3 autoantibodies lead to steric hindrance 
in desmoglein interaction, altered cellular signaling, and aberrant 
cellular distribution of desmogleins resulting in acantholysis, 
the formation of flaccid blisters and erosions (11, 12). The events 
that lead to the irregular production of autoantibodies are largely 
unknown. While PV is known to be strongly associated with 
certain HLA alleles, such as DRB1*0402 and DQB1*0503, we 
have recently described an association with the first non-HLA 
gene, ST18, in PV patients from Egypt and Israel, but not from 
Germany (13, 14). Moreover, PV susceptibility was found to be 
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associated with certain polymorphisms of FcγRIIb and FcγRIIc, 
indicating a role of peripheral tolerance in this disease (15). Here, 
we followed up on the idea of non-HLA susceptibility genes 
in pemphigus and investigated a possible association with the 
functionally important p.Arg435His variation of IgG3.
MaTerials anD MeThODs
Description of cohorts
Samples and controls were stored and analyzed in the order in 
which they were collected, irrespective of age and gender. The 
inclusion criteria for PV and BP followed the recent guidelines 
of the German Society of Dermatology and European Academy 
of Dermatology and Venereology (16–18). In brief, PV was 
diagnosed based on the clinical picture with flaccid blisters and/
or erosions on the skin and/or surface-close mucous membranes, 
intercellular IgG and/or C3 deposition in the epidermis/epithelia 
by direct immunofluorescence and/or detection of circulating 
anti-desmoglein 3 autoantibodies. In BP, diagnosis was made in 
patients with compatible clinical picture, i.e., tense blisters, ero-
sions, prurigo-type lesions, and urticarial or eczematous lesions 
(19), deposition of IgG and/or C3 at the dermal–epidermal junc-
tion by direct immunofluorescence microscopy, and/or detection 
of serum BP180 NC16A IgG. The respective diagnosis was re-
evaluated in the Department of Dermatology, Lübeck, Germany. 
Normal healthy controls were defined not to match any of the 
above criteria.
allotype-specific elisa
The G3m15 allotype was detected with a sandwich ELISA using 
the same single chain Fv (scFv) for capture and detection, as 
described (2). Briefly, microtiter plates (Nalge Nunc International, 
Rochester, NY, USA) were coated with anti-hIgG3 G3m15 scFv 
[1.5A10 anti G3m(s,t)] at 5  µg/ml in carbonate buffer, pH 9.6. 
After washing with phosphate-buffered saline (PBS)/0.05% 
Tween-20 (PBST), plates were blocked with 1% biotin-free BSA 
(Carl Roth GmbH, Karlsruhe, Germany) in PBST (1% BSA in 
PBST). After washing, serum samples and the positive control 
G3m15 diluted in 1% BSA in PBST were loaded onto the plates 
and incubated for 2 h. For detection, plates were incubated with 
biotin-conjugated anti-hIgG3 G3m15 scFv, diluted at 5 µg/ml in 
1% BSA in PBST, followed by peroxidase-conjugated streptavi-
din (Dako Deutschland GmbH, Hamburg, Germany) diluted 
1:2,000 in 1% BSA in PBST. For colorimetric detection, plates 
were developed using TurboTMB (Perbio Science Deutschland 
GmbH, Bonn, Germany) and stopped with 1 M H2SO4 solution. 
OD values were measured at 450 nm using a VICTOR 3™ reader 
(PerkinElmer Inc., Waltham, MA, USA).
Determination of the rs4042056 genotype 
by KasP assay
The genotype of the rs4042056 was determined with the KASP 
method (LGC Genomics GmbH, Berlin, Germany), using a 
customized assay on a realplex2 Mastercycler (Eppendorf AG, 
Hamburg, Germany), followed by fluorescence end-point reading 
with an Applied Biosystems 7800 Real-Time PCR system (Life 
Technologies GmbH, Darmstadt, Germany). For each sample, 
10 ng of genomic DNA was used and mixed with KASP reagents 
according to the manufacturer. The KASP assay contained the 
allele-specific HEX-conjugated primer 5′-ggc tct tct gcg tga agc-
3′, the FAM-conjugated primer 5′-ggc tct tct gcg tga agt-3′, and 
the common primer 5′-cag gtg gca gca ggg gaa ca-3′.
amplification of the rs4042056 Flanking 
sequence
The gene sequence flanking the rs4042056 in the human IgG3 
gene was amplified by PCR using the forward primer 5′-cag gtg 
gca gca ggg gaa ca-3′ and the reverse primer 5′-cgg ccg tcg cac tca 
ttt ac-3′, resulting in a 112 bp product (Figure S1 in Supplementary 
Material). After agarose gel purification with the QIAquick Gel 
Extraction Kit (Qiagen, Hilden, Germany), this product was 
subjected to Sanger sequencing at Eurofins Genomics, Ebersberg, 
Germany, using the same primers. For PCR, HotStart Phusion 
polymerase (Life Technologies GmbH, Darmstadt, Germany) 
was used with Phusion HiFidelity buffer, 1% DMSO and 10 pmol 
of each primer. PCR program: 98°C for 30 s; 10 cycles of 98°C for 
5 s, 75°C (−1.0°C/cycle) for 20 s, 72°C 10 s; 25 cycles of 98°C for 
5 s, 65°C for 20 s, 72°C 10 s; final elongation for 5 min at 72°C.
statistical analysis
The open-source software GNU R version 3.152 was used for 
statistical analysis, together with the package lme4 for general-
ized linear mixed effects regression of co-dominant, recessive 
and dominant genetic effects, including stratification by ethnic 
cohort. For cohort-wise analyses, Lidstone additive smoothing 
was applied by addition of a pseudocount of α = 0.5.
For combined analyses of serum and DNA samples, the 
generalized linear mixed effects regression was extended by using 
both sample type and ethnic cohort as stratification factors.
For comparison of genotyping results between different meth-
ods, Cohen’s weighted kappa was calculated using the function 
cohen.kappa in package psych. Hardy–Weinberg equilibrium 
was checked with the function HWAlltests from the R package 
HardyWeinberg.
To compare genotype frequencies determined in sera or DNA 
samples, we used a logistic regression with the risk allotype/
allele as response variable and sample type (or genotyping 
method), ethnic origin and disease state (PV vs. healthy control) 
as covariates, including all two- and three-way interactions. For 
calculation of likelihood-ratio test p values, the function Anova 
from R package car was applied.
resulTs
We collected genomic DNA or serum samples from 516 PV 
patients and 555 population-matched healthy controls from 
Germany (n =  137 patients, n =  259 controls), Iran (n =  78 
patients, n =  90 controls), Turkey (n =  148 patients, n =  19 
controls), and Egypt (n = 153 patients, 197 controls) (Table 1). 
Furthermore, DNA or serum from 173 German patients with 
2 http://www.R-project.org/ (Accessed: 27 February, 2018).
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BP, another autoimmune blistering skin disease associated with 
autoantibodies against BP180 (collagen type XVII), was analyzed 
(Table 2) (20). Separate cohorts were applied for serum and DNA 
samples.
Designing a PCR-based genotyping method for process-
ing large sample numbers turned out to be challenging. The 
primer combination had to be specific for the IgG3 subclass 
and at the same time, should amplify most of the known 
allotypes and differentiate between the two allelic variants of 
the rs4042056 SNP (minor allele: g.1053927G>A, Figure  1). 
For this purpose, the Kompetitive Allele-Specific PCR method 
(KASP™) appeared to be appropriate. The selectivity for the 
IgG3 gene is provided by a 3′ base (G/A) mismatch of the 
common primer with the sequence of IgG1, IgG2, and IgG4 
gene. This mismatch also suppresses amplification in case of the 
IGHG3*03 allele [rs79545032, g.105769317A>G, minor allele 
frequency (MAF) 4% in and 16% in African populations (21)], 
but 17 of the 19 IgG3 gene alleles listed in the IMGT database 
were matching the primer sequence sufficiently. To verify the 
results of the KASP assay we amplified the region flanking the 
g.1053927G>A variation in the IgG3 gene by PCR in a small 
number of samples representing the different genotypes. The 
genotype of this SNP was determined using Sanger sequenc-
ing (Figure S1 in Supplementary Material). The comparison 
showed that both methods were correlating well [Table S1 in 
Supplementary Material, Cohen’s weighted kappa = 0.62 (95% 
CI: 0.39–0.85), Fisher’s exact test p = 0.0054]. Furthermore, we 
used a fully saturated logistic regression model to evaluate the 
dependency of genotype frequencies on disease status, genotyp-
ing method, ethnic origin and all possible interactions between 
those. The likelihood ratio test revealed that only disease status 
(p = 0.002) and ethnic origin (p = 0.0095) show a significant 
influence on the genotype frequency, while the genotyping 
method—and any interaction of genotyping method with the 
other covariates—did not have an effect. This confirms that 
both genotyping methods are equivalent, and it indicates the 
frequency of the p.Arg435His variation is more common in 
MENA countries.
For serum samples (n =  177 patients, n =  136), we used a 
sandwich ELISA to serologically determine the G3m15 allotype 
that is described to be linked to the p.Arg435His variation (2) 
(Table 1). The MAF estimation for the p.Arg435His variation did 
not differ significantly between the results from the KASP assay 
(3.3% in cases and 0.5% in controls) and the ELISA (2% in cases 
and 1.1% in controls). Moreover, the frequencies of the G3m15 
allotype and the p.Arg435His variation were different in cases 
and controls especially in the Egyptian and the Turkish popula-
tions. The distribution of genotypes was not in Hardy–Weinberg 
equilibrium for all cohorts of PV cases and in the Iranian cohort 
of controls.
To test if our finding for p.Arg435His variation in PV was 
a general phenomenon for all autoimmune blistering diseases 
(20) a cohort of n = 173 German patients with BP was used. In 
this cohort of BP patients, no significant association of disease 
risk with the p.Arg435His or the G3m15 allotype was observed 
(Table 2). The genotype distribution of BP cases had no Hardy-
Weinberg equilibrium.
DiscussiOn
Allotypic variation has been associated with various autoim-
mune diseases including autoimmune blistering skin diseases 
(6, 7). However, the functional role of allotypic variation is 
mostly unknown with the exception of the p.Arg435His variation 
which has been demonstrated to affect the half-life of IgG3 (2). 
We hypothesized that such a functionally relevant variation 
should be important for the susceptibility of autoantibody-
mediated diseases like PV and BP.
High-throughput genotyping of the p.Arg435His variation is 
hampered by a high variability of the target gene region on the one 
hand, and a high degree of homology between IgG3 and the other 
three IgG subclass genes. We were able to design a genotyping 
method based on KASP technology, but this method did not dis-
criminate heterozygotes from homozygotes. To check the results 
of this method in a subset of samples representing all detectable 
genotypes, we used PCR amplification and Sanger sequencing 
which overall confirmed the validity of the KASP assay. Using 
the KASP assay, we could demonstrate an association between 
the p.Arg435His variation and PV in the combined analyses of all 
ethnic groups, and within the group of German patients. Analysis 
within the other ethnic groups showed no significant association. 
This is most probably related to smaller cohort sizes, compared 
with the German one, because the odds ratio ranged between 1 
and 3 in all ethnic cohorts.
As a secondary method for genotyping, we used an ELISA 
method that detects an amino acid variation which is, according 
to IMGT databases, linked to the p.Arg435His variation. Using 
this method alone, we could not find any association with PV 
disease, which might be explained by the overall lower number 
of available serum samples in the cohort. However, combining 
ELISA with KASP genotyping data, using genotyping method 
and ethnic origin for stratification in a mixed effects logistic 
regression analysis, reaffirmed the results gained by KASP assay 
alone. Furthermore, the genotype frequencies of cohorts did not 
differ significantly between the genotyping methods. Therefore, 
our results confirm that both genotyping by KASP assay and 
ELISA lead to equivalent results.
The IgG subclass of autoantibodies in PV is most frequently 
IgG4, followed by IgG1 (9). IgG2 and IgG3 are found in only spo-
radically. However, this does not exclude the possibility that the 
prolonged half-life of IgG3 with the p.Arg435His variation could 
affect very early preclinical stages of PV. IgG3 is the often first 
IgG subclass a B cell switches to from IgM, before IgG1 and IgG4 
(10). Very early autoantibodies are possibly involved in feedback 
loops that self-promote autoimmune responses (22). In this sce-
nario, the p.Arg435His variation might enhance these feedback 
loops by its ability to increase the half-life and biodistribution 
of these autoantibodies as well as the processing of IgG3-bound 
autoantigen by enhanced phagocytosis (3). We may speculate that 
the higher susceptibility to PV associated with the p.Arg435His 
variation is related to the altered promotion of preclinical PV to 
the clinically manifest disease. As an alternative explanation, the 
genomic region flanking the p.Arg435His variation might lead 
to a changed class switching behavior, as it has been shown for 
the G3m(b) (Figure 1, G3m5* allotype in current nomenclature) 
Table 1 | IgG3 rs4042056 variation in pemphigus vulgaris by KASP assay.
KasPa cases controls recessivec Dominantc co-dominantc
rs4042056 aa ag gg MaF (%)b aa ag gg MaF (%)b Or (95% ci) p Or (95% ci) p Or (95% ci) p
Germany 4 0 83 4.6* 0 1 180 0.28 19 (1–350) 0.0074 5.2 (1–27) 0.037 3.2 (1.1–9.5) 0.014
4.6% 0% 95% 0% 0.55% 99%
Iran 5 1 72 7.1* 3 0 87 3.3* 1.9 (0.5–7.4) 0.37 2.1 (0.6–7.5) 0.24 1.4 (0.7–2.8) 0.28
6.4% 1.3% 92% 3.3% 0% 97%
Turkey 9 1 63 13* 0 0 19 0 5.8 (0.33–100) 0.12 3.4 (0.4–28) 0.19 2.2 (0.6–7.6) 0.15
12% 1.4% 86% 0% 0% 100%
Egypt 2 0 99 2* 0 0 126 0 6.4 (0.3–130) 0.16 6.4 (0.3–130) 0.16 2.5 (0.6–12) 0.16
2% 0% 98% 0% 0% 100%
Totalg 20 2 317 6.2 3 1 412 0.84 4.28 (1.6–11.9) 0.0051 3.7 (1.5–9) 0.0038 2.78 (1.0–7.6) 0.047
5.9% 0.6% 94% 0.7% 0.2% 99%
elisad cases controls Dominantc elisa/KasP combined 
dominanth
g3m15 Positive negative MaF (%)e Positive negative MaF (%)e Or (95% ci) p Or (95% ci) p
Germany 1 49 1.0 1 77 0.6 1.6 (0.2–15) 0.7 4.9 (0.9–25.4) 0.061
2.0% 98.0% 1.3% 98.7%
Iran n.a.f n.a.f n.a.f n.a.f n.a.f n.a.f n.a. n.a. n.a. n.a.
Turkey 4 71 2.7 n.a.f n.a.f n.a.f n.a. n.a. n.a. n.a.
5.3% 94.7%
Egypt 2 50 1.9 2 59 1.7 1.6 (0.33–8) 0.54 2.5 (0.4–13.7) 0.298
3.8% 96.2% 3.3% 96.7%
Totalg 7 170 2 3 136 1.1 1.75 (0.4–7.6) 0.83 3.6 (1.5–8.8) 0.0041
4% 96% 2.2% 97.8%
aThe KASP assay directly determined the genotype of rs4042056 SNP that corresponds to the amino acid at residue 435. The minor A allele (g.1053927G>A) allele corresponds to p.Arg435His.
bMAF, minor allele frequency, i.e., frequency of the A allele. An asterisk (*) indicates that the respective genotype distribution is not in Hardy–Weinberg equilibrium.
cLogistic regression (recessive, dominant, and co-dominant models) stratified by ethnic cohort. The 95% confidence interval is given for the odds ratio (OR); the p value (p) is given for the likelihood ratio test (LR test) on the genotype. 
For origin-wise models, the raw ORs are shown. In the combined analysis, a generalized linear mixed effects (with implicit adjustment) model with logit link function was applied. In case of 0 values in corresponding data, Lidstone 
additive smoothing was used to allow calculation of ORs and ensure convergence of the fitting routine.
dThe ELISA detects the G3m15 allotype of IgG3 that is linked to the p.Arg435His variation.
eMAF, minor allele frequency, i.e., frequency of the allele encoding the G3m15 allotype, inferred assuming Hardy–Weinberg equilibrium.
fn.a., no serum samples available.
gRegression calculated with a generalized linear mixed effects model (uncorrelated intercept and genotype effect as random effects).
hLogistic regression of combined ELISA and KASP results. The genotyping method was used for stratification in a random effects model (compare table footnote c). For the calculation across all ethnicities, ethnic origin was used 
together the genotyping method for stratification.
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and G3m(g) (Figure 1, G3m21* allotype in current nomencla-
ture) allotype (23). This alternative explanation assumes that the 
antibody repertoire is changed generally in way that promotes 
development of PV, but does not require the existence of early 
IgG3 autoantibodies.
In case of BP, other mechanisms might be important for the dis-
ease development. This is not only reflected by differences between 
PV and BP concerning associations with FcγR polymorphisms 
(15), but also, as found here, concerning the p.Arg435His varia-
tion that does not appears to be associated with BP susceptibility.
A study with individuals from malaria-endemic regions in 
Benin showed that anti-malaria IgG3 is transferred from pregnant 
mothers with the p.Arg435His variation to their unborn children and 
that these children have an improved immunoprotection against 
malaria (24). In our cohorts, we could find an increased frequency 
of the minor g.1053927G>A (p.Arg435His) allele in the patient 
cohorts from Iran and Turkey, in contrast to Egypt and Germany. 
Iran and Turkey are denoted as malaria-endemic countries from the 
U.S. Centers of Disease Control, while Egypt and Germany are not 
(25). A connection between malaria and pemphigus diseases has 
not been described, yet. Malaria is transmitted by stinging insects. 
This is remarkable, because in endemic Pemphigus foliaceus in 
Brazil, a connection to stinging insects has been described: autoan-
tibodies against desmoglein 1 from affected patients cross-react 
with a salivary protein of a biting fly (26, 27). A genetic test does 
not allow to distinguish a direct effect of variation on susceptibility 
to a disease from a population effect. Our data show that the fre-
quency of the p.Arg435His variation is higher in Iran and Turkey, 
favors the assumption of Dechavanne et  al., that this variation 
could be an evolutionary adaption to malaria (24). Though highly 
speculative, a link between malaria and PV, be it genetic or envi-
ronmental, would provide an alternative or additional explanation 
for the association between PV and the p.Arg435His variation: 
PV patients might preferably come from malaria-endemic areas 
within the investigated countries, while controls do not have this 
preference, leading to an increased frequency of the p.Arg435His 
variation. Such a population effect cannot be distinguished with 
the data available. However, a population effect would not imply 
any direct functional effect of the p.Arg435His variation on PV 
susceptibility or a theoretical involvement of IgG3 in PV.
The Hardy–Weinberg equilibrium assumption did not hold in 
any of the PV case cohorts. Next to the above described technical 
challenges, population effects as described above and the known 
high degree of consanguinity in the investigated populations 
could explain this phenomenon (28).
In summary, we found an association of PV but not of BP with 
a genetic variation that is known to change half-life and effector 
functions of IgG3. These data suggest that IgG3 may play a role 
in the pathogenesis of PV or that there may be a link between 
malaria or malaria-transmitting mosquitoes and PV in MENA 
countries.
The gerMan aibD geneTic sTuDY 
grOuP MeMbers
Alexander Kreuter, Department of Dermatology, Venereology 
and Allergology, University of Bochum, Bochum, Germany 
7Recke et al. Association of IgG3 Allotypes With PV Susceptibility
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1788
(current affiliation: Department of Dermatology, Venereology 
and Allergology, HELIOS St. Elisabeth Klinik Oberhausen, 
Oberhausen, Germany); Christos C. Zouboulis, Department 
of Dermatology, Venereology, Allergology and Immunology, 
Dessau Medical Center, Dessau, Germany; Georg Däschlein, 
Department of Dermatology, University of Greifswald, 
Greifswald, Germany; Kerstin Steinbrink, Department of 
Dermatology, University Medical Center Mainz, University 
of Mainz, Mainz, Germany; Manfred Kunz, Department of 
Dermatology, Venereology and Allergology, University of 
Leipzig, Leipzig, Germany; Nicolas Hunzelmann, Department 
of Dermatology, University of Cologne, Cologne, Germany; 
Steven Goetze, Department of Dermatology, University 
Hospital Jena, Jena, Germany.
eThics sTaTeMenT
This study was carried out in accordance with the recom-
mendations of institutional review board of the University of 
Lübeck and the review boards of the collaborating centers. The 
protocol was approved by the institutional review board of the 
University of Lübeck (File No. 08-156) and the review boards 
of the collaborating centers. All subjects gave written informed 
consent in accordance with the Declaration of Helsinki. 
Samples and demographic data of patients and controls were 
collected in adherence to ethics and German privacy protection 
regulations.
auThOr cOnTribuTiOns
AR designed research, performed experiments, analyzed data, 
interpreted results, and wrote the manuscript; SK performed 
experiments, analyzed data, and wrote the manuscript; SL inter-
preted results and wrote the manuscript; MF performed experi-
ments and analyzed data; NS, MA, SB, FE-C, ME, RE, RG, CG, 
EH, BH, WL, WP, RR, MSaeedi, MSárdy, MSticherling, SU, MW, 
and DZ recruited patients and organized sample collections; SI 
designed research, interpreted results, and wrote the manuscript; 
GV designed research, interpreted results, and wrote the manu-
script; ES recruited patients, interpreted results, and wrote the 
manuscript; the German AIBD Genetic Study Group organized 
sample collections.
acKnOWleDgMenTs
We thank everybody involved in the collection of blood samples 
and all volunteers and patients who donated blood for this study. 
This work received infrastructural support from the Deutsche 
Forschungsgemeinschaft Cluster of Excellence Inflammation at 
Interfaces (Cluster 306/2).
suPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01788/
full#supplementary-material.
reFerences
1. Recke A, Sitaru C, Vidarsson G, Evensen M, Chiriac MT, Ludwig RJ, et al. 
Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of 
dermal-epidermal separation. J Autoimmun (2010) 34:435–44. doi:10.1016/j.
jaut.2009.11.003 
2. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, 
Gerritsen J, et al. Competition for FcRn-mediated transport gives rise to short 
half-life of human IgG3 and offers therapeutic potential. Nat Commun (2011) 
2:599. doi:10.1038/ncomms1608 
3. Stapleton NM, Einarsdóttir HK, Stemerding AM, Vidarsson G. The multiple 
facets of FcRn in immunity. Immunol Rev (2015) 268:253–68. doi:10.1111/
imr.12331 
4. Lefranc G, Chaabani H, Van Loghem E, Lefranc MP, De Lange G, Helal AN. 
Simultaneous absence of the human IgG1, IgG2, IgG4 and IgA1 subclasses: 
immunological and immunogenetical considerations. Eur J Immunol (1983) 
13:240–4. doi:10.1002/eji.1830130312 
5. Lefranc M-P, Lefranc G. Human Gm, Km, and Am allotypes and their mole-
cular characterization: a remarkable demonstration of polymorphism. Methods 
Mol Biol (2012) 882:635–80. doi:10.1007/978-1-61779-842-9_34 
6. Pressler T, Pandey JP, Espersen F, Pedersen SS, Fomsgaard A, Koch C, et al. 
Immunoglobulin allotypes and IgG subclass antibody response to Pseudo-
monas aeruginosa antigens in chronically infected cystic fibrosis pati ents. 
Clin Exp Immunol (1992) 90:209–14. 
7. Zitouni M, Martel P, Ben Ayed M, Raux G, Gilbert D, Joly P, et al. Pemphigus 
is not associated with allotypic markers of immunoglobulin kappa. Genes 
Immun (2002) 3:50–2. doi:10.1038/sj.gene.6363817 
8. Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O’Leary CE, Payne AS. 
Enrichment of total serum IgG4 in patients with pemphigus. Br J Dermatol 
(2012) 167:1245–53. doi:10.1111/j.1365-2133.2012.11144.x 
9. Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T. 
Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foli-
aceus. J Dermatol Sci (2001) 26:55–61. doi:10.1016/S0923-1811(00)00158-4 
10. Jackson KJL, Wang Y, Collins AM. Human immunoglobulin classes and 
subclasses show variability in VDJ gene mutation levels. Immunol Cell Biol 
(2014) 92:729–33. doi:10.1038/icb.2014.44 
11. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal 
scalded-skin syndrome. N Engl J Med (2006) 355:1800–10. doi:10.1056/
NEJMra061111 
12. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, 
Payne AS, et al. Pemphigus. Nat Rev Dis Primers (2017) 3:17026. doi:10.1038/
nrdp.2017.26 
13. Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, et  al. 
Population-specific association between a polymorphic variant in ST18, 
encoding a pro-apoptotic molecule, and pemphigus vulgaris. J Invest Dermatol 
(2012) 132:1798–805. doi:10.1038/jid.2012.46 
14. Sinha AA, Brautbar C, Szafer F, Friedmann A, Tzfoni E, Todd JA, et al. A newly 
characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 
(1988) 239:1026–9. doi:10.1126/science.2894075 
15. Recke A, Vidarsson G, Ludwig RJ, Freitag M, Möller S, Vonthein R, et  al. 
Allelic and copy-number variations of FcγRs affect granulocyte function and 
susceptibility for autoimmune blistering diseases. J Autoimmun (2015) 61: 
36–44. doi:10.1016/j.jaut.2015.05.004 
16. Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, et al. 
Management of bullous pemphigoid: the European Dermatology Forum 
consensus in collaboration with the European Academy of Dermatology and 
Vener eology. Br J Dermatol (2015) 172:867–77. doi:10.1111/bjd.13717 
17. Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, et  al. 
Pemphigus. S2 guideline for diagnosis and treatment – guided by the European 
Dermatology Forum (EDF) in cooperation with the European Academy of 
Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol (2015) 
29:405–14. doi:10.1111/jdv.12772 
18. Schmidt E, Goebeler M, Hertl M, Sárdy M, Sitaru C, Eming R, et  al. S2k 
guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous 
pemphigoid. J Dtsch Dermatol Ges (2015) 13:713–27. doi:10.1111/ddg. 
12612 
8Recke et al. Association of IgG3 Allotypes With PV Susceptibility
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1788
19. Schmidt E, della Torre R, Borradori L. Clinical features and practical 
diagnosis of bullous pemphigoid. Dermatol Clin (2011) 29:427–438,viii–ix. 
doi:10.1016/j.det.2011.03.010 
20. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet (2013) 381:320–32. 
doi:10.1016/S0140-6736(12)61140-4 
21. Clarke L, Fairley S, Zheng-Bradley X, Streeter I, Perry E, Lowy E, et al. The 
international Genome sample resource (IGSR): a worldwide collection of 
genome variation incorporating the 1000 Genomes Project data. Nucleic Acids 
Res (2017) 45:D854–9. doi:10.1093/nar/gkw829 
22. Hjelm F, Carlsson F, Getahun A, Heyman B. Antibody-mediated regulation 
of the immune response. Scand J Immunol (2006) 64:177–84. doi:10.1111/ 
j.1365-3083.2006.01818.x 
23. Pan Q, Rabbani H, Mills FC, Severinson E, Hammarström L. Allotype-
associated variation in the human gamma3 switch region as a basis for 
differences in IgG3 production. J Immunol (1997) 158:5849–59. 
24. Dechavanne C, Dechavanne S, Sadissou I, Lokossou AG, Alvarado F, 
Dambrun M, et al. Associations between an IgG3 polymorphism in the binding 
domain for FcRn, transplacental transfer of malaria-specific IgG3, and protec-
tion against Plasmodium falciparum malaria during infancy: a birth cohort study 
in Benin. PLoS Med (2017) 14:e1002403. doi:10.1371/journal.pmed.1002403 
25. Brunette GW, Centers for Disease Control (U.S.). CDC Yellow Book 2018: 
Health Information for International Travel. Oxford, UK: Oxford University 
Press (2017).
26. Aoki V, Millikan RC, Rivitti EA, Hans-Filho G, Eaton DP, Warren SJP, 
et al. Environmental risk factors in endemic pemphigus foliaceus (fogo 
selvagem). J Investig Dermatol Symp Proc (2004) 9:34–40. doi:10.1111/j.1087- 
0024.2004.00833.x 
27. Qian Y, Jeong JS, Maldonado M, Valenzuela JG, Gomes R, Teixeira C, et al. 
Cutting edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoanti-
bodies cross-react with sand fly salivary LJM11 antigen. J Immunol (2012) 
189:1535–9. doi:10.4049/jimmunol.1200842 
28. Barbouche M-R, Mekki N, Ben-Ali M, Ben-Mustapha I. Lessons from genetic 
studies of primary immunodeficiencies in a highly consanguineous popula-
tion. Front Immunol (2017) 8:737. doi:10.3389/fimmu.2017.00737 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Recke, Konitzer, Lemcke, Freitag, Sommer, Abdelhady, Amoli, 
Benoit, El-Chennawy, Eldarouti, Eming, Gläser, Günther, Hadaschik, Homey, 
Lieb, Peitsch, Pföhler, Robati, Saeedi, Sárdy, Sticherling, Uzun, Worm, Zillikens, 
Ibrahim, Vidarsson, Schmidt and the German AIBD Genetic Study Group. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other 
forums is permitted, provided the original author(s) and the copyright owner(s) 
are credited and that the original publication in this journal is cited, in accor-
dance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
